companies / raytherapeutics-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-13 json
| total_raised | 200,000,000200.0M | ○ |
|---|---|---|
| founded | 2018 | |
| hq | San Francisco | |
| industry | unknown | |
| stage | series-b+ |
Ray Therapeutics develops optogenetic gene therapies for degenerative retinal diseases, reprogramming surviving retinal neurons to sense light and signal the brain. It targets patients with blinding conditions such as retinitis pigmentosa and Stargardt disease. Rather than replacing damaged cells, it repurposes neurons that remain after disease.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-04-24 | series-b | 125,000,000125.0M | null | ○ |
Cloudflare, Typekit, Adobe Fonts, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, Elementor 3.28.3, DoubleClick Floodlight, Cloudflare Bot Management, WP Engine, WPMU DEV Smush 3.23.1, Python
| fact | status | src |
|---|---|---|
| Series B, $125.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |